

REFERENCIAS:

1. King A, MacDonald C, Örn C. Understanding gastroesophageal reflux disease: a patient cluster analysis. *Int J Clin Pract* 2008;62:1838–43. **2.** Bell N, Burget D, Howden C, Wilkinson J, Hunt R. Appropriate acid suppression for the management of gastroesophageal reflux disease. *Digestion* 1992;51 Suppl 1:59–67. **3.** Joelsson B, Johnsson F. Heartburn – the acid test. *Gut* 1989;30:1523–5. **4.** Nexium Product Monograph, 5th edition, 2010 AstraZeneca. **5.** Katz P, Ginsberg G, Hoyle P, Sostek M, Monyak J, Silberg D. Relationship between intragastric acid control and healing status in the treatment of moderate to severe erosive esophagitis. *Aliment Pharmacol Ther* 2007;25:617–28. **6.** Dent J. Roles of gastric acid and pH in the pathogenesis of gastro-oesophageal reflux disease. *Scand J Gastroenterol* 1994;29 Suppl:55–61. **7.** Berstad A. A modified hemoglobin substrate method for the estimation of pepsin in gastric juice. *Scand J Gastroenterol* 1970;5:343–8. **8.** Castell D, Kahrilas P, Richter J, Vakil N, Johnson D, Zuckerman S et al. Esomeprazole (40 mg) compared with lansoprazole (30 mg) in the treatment of erosive esophagitis. *Am J Gastroenterol* 2002;97:575–83. **9.** Kahrilas P, Falk G, Johnson D, Schmitt C, Collins D, Whipple J et al. Esomeprazole improves healing and symptom resolution as compared with omeprazole in reflux esophagitis patients: a randomized controlled trial. *Aliment Pharmacol Ther* 2000;14:1249–58. **10.** Labenz J, Armstrong D, Lauritsen K, Katerlaris P, Schmidt S, Schütze K et al. A randomised comparative study of esomeprazole 40 mg versus pantoprazole 40 mg for healing erosive oesophagitis: the EXPO study. *Aliment Pharmacol Ther* 2005;21:739–46. **11.** Richter J, Kahrilas J, Johanson J, Maton P, Breiter J, Hwang C et al. Efficacy and safety of esomeprazole compared with omeprazole in GERD patients with erosive esophagitis: a randomized controlled trial. *Am J Gastroenterol* 2001;96:656–65. **12.** Miner P, Katz P, Chen Y, Sostek M. Gastric acid control with esomeprazole, lansoprazole, omeprazole, pantoprazole, and rabeprazole: a five-way crossover study. *Am J Gastroenterol* 2003;98:2616–20. **13.** Miner P Jr, Katz PO, Chen Y, Sostek M. Reanalysis of intragastric pH results based on updated correction factors for Slimline and Zinetics™ 24 single-use pH catheters. *Am J Gastroenterol* 2006;101:404–5, 406. **14.** Röhss K, Lind T, Wilder-Smith C. Esomeprazole 40 mg provides more effective intragastric acid control than lansoprazole 30 mg, omeprazole 20 mg, pantoprazole 40 mg and rabeprazole 20 mg in patients with gastro-oesophageal reflux symptoms. *Eur J Clin Pharmacol* 2004;60:531–9. **15.** Röhss K, Hasselgren G, Hedenström H. Effect of esomeprazole 40 mg vs omeprazole 40 mg on 24-hour intragastric pH in patients with symptoms of gastroesophageal reflux disease. *Dig Dis Sci* 2002;47:954–8. **16.** Edwards SJ, Lind T, Lundell L. Systematic review: proton pump inhibitors (PPIs) for the healing of reflux oesophagitis – a comparison of esomeprazole with other PPIs. *Aliment Pharmacol Ther* 2006;24:743–50. **17.** Labenz J, Armstrong D, Lauritsen K, Katerlaris P, Schmidt S, Schütze K, Wallner G, Juergens H, Preiksaitis H, Keeling N, Nauder E, Adler J, Eklund S. Esomeprazole 20 mg vs. pantoprazole 20 mg for maintenance therapy of healed erosive oesophagitis: results from the EXPO study. *Aliment Pharmacol Ther*. 2005;22(9):803–11. **18.** Lauritsen K, Devière J, Bigard MA, Bayerdörffer E, Mózsik G, Murray F, Kristjánsdóttir S, Savarino V, Vetvik K, De Freitas D, Orive V, Rodrigo L, Fried M, Morris J, Schneider H, Eklund S, Larkö A; Metropole study results. Esomeprazole 20 mg and lansoprazole 15 mg in maintaining healed reflux oesophagitis: Metropole study results. *Aliment Pharmacol Ther*. 2003;17(3):333–41. **19.** Talley N, Lauritsen K, Tunturi-Hihnala H, Lind T, Moum B, Bang B et al. Esomeprazole 20 mg maintains symptom control in endoscopy-negative gastro-oesophageal reflux disease: a controlled trial of 'on-demand' therapy for 6 months. *Aliment Pharmacol Ther* 2001;15:347–54. **20.** Talley N, Venables T, Green J, Armstrong D, O’Kane K, Gjaffer M et al. Esomeprazole 40 mg and 20 mg is efficacious in the long-term management of patients with endoscopy negative gastro-oesophageal reflux disease: a placebo controlled trial of on-demand therapy for 6 months. *Eur J Gastroenterol Hepatol* 2002;14:857–63.